Thomas Byrne

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Diffusion Pharmaceuticals LLC develops and manufactures pharmaceutical products. The firm develops trans sodium crocetinate for use in cancers types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. The company was founded by Matthew W. Hantzmon, John L. Gainer, and David G. Kalergis in February 2001 and is headquartered in Charlottesville, VA.

Nixon & Vanderhye P.C. engages in the provision of legal services. It offers patent prosecution and litigation, trademarks, post grant proceedings, internet protocol due diligence, and transactional practice, licensing, and copyrights services. The firm serves the biotechnology and life sciences, chemical and pharmaceutical, electronics, computer technology, communications and software, and the mechanical arts industries. The company was founded in 1985 and is headquartered in Arlington, VA.

RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL.

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.